[Clinical experiences with oral antidiabetic HB 419 (glibenclamide)].
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001772:Blood Cell Count; D001786:Blood Glucose / Q000032:analysis; D001792:Blood Platelets; D001835:Body Weight / Q000187:drug effects; D002241:Carbohydrates / Q000652:urine; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011537:Pruritus / Q000139:chemically induced; D014508:Urea / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D001786:Blood Glucose; D002241:Carbohydrates; D007004:Hypoglycemic Agents; D014508:Urea; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase
Klinische Erfahrungen mit dem oralen Antidiabeticum HB 419 (Glibenclamid)